Category: Interviews
Longevity Advocacy in 2025: The Expert Roundup
January 15, 2026
The last installment in our end-of-year series of expert roundups might be the least flashy, but it is arguably no less important than the previous ones dedicated to longevity biotech
Geroscience in 2025: The Expert Roundup
January 13, 2026
2025 was a good year for geroscience, marked by rapid strides and critical milestones. Yet, the path wasn’t always smooth: progress in some areas lagged, research hit dead ends, and
Longevity Biotech in 2025: The Expert Roundup
January 6, 2026
How did the year 2025 turn out for longevity biotech? Was it surprising or more of the same? Exciting or disappointing? Was the progress fast-moving or excruciatingly slow? What should
Maximina Yun on the Wonders of the Axolotl
December 19, 2025
Dr. Maximina Yun, principal investigator at Chinese Institutes for Medical Research in Beijing (CIMR), studies some of the most amazing animals in the world: salamanders, a group of amphibians that
Andrea Maier on Longevity Medicine for All
October 22, 2025
Dr. Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is a veteran geroscientist and one of the most familiar faces in the rising field
Sam Sharifi on Fixing Our DNA
October 3, 2025
Among the hallmarks of aging, DNA damage is both one of the most important and one of the hardest to crack. A couple of years ago, when I first learned
Joe Betts-Lacroix on Retro Bio and Its Recent AI Advancement
October 2, 2025
Retro Biosciences, one of the hottest startups in the longevity field, was founded about five years ago by the tech entrepreneur Joe Betts-Lacroix with a $180 million investment from his
Nir Barzilai: “Positive Evidence for Metformin is Mounting”
August 12, 2025
Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine, among his many other titles, is one of geroscience’s most prominent figures.
Gabriel Cian on Investment and the 2060 Longevity Forum
July 10, 2025
In this Lifespan interview, we speak with Gabriel Cian, founder of the 2060 Longevity Forum, about how his background in software shaped his views on healthspan innovation, the forum’s approach
Dr. David Furman on Inflammation and Aging
July 7, 2025
The longevity field hasn’t been very good at naming things, but one notable exception is “inflammaging”: the low-grade chronic inflammation that correlates with aging. Recognition has been growing that inflammation,
Boyang Wang on Targeting Underfunded Longevity Projects
June 9, 2025
In this interview, Boyang Wang of Immortal Dragons discusses the kinds of projects he wants to fund, ways in which the industry can be encouraged to develop, relationships between the
Rejuve.AI: Just Another App or a Longevity Research Network?
June 5, 2025
On its website, Rejuve.AI, a company co-founded by its dynamic CEO, Jasmine Smith, and a renowned AI researcher, Ben Goertzel, promises a lot of things: to “democratize longevity, globally,” to
Michael Levin on Bioelectricity in Development and Aging
May 8, 2025
Michael Levin, professor at Tufts University and director of Allen Discovery Center, has been working for years on how bioelectrical patterns affect development and aging. His research proves that this
Joshua “Scotch” McClure: “Infectious Disease Drives Aging”
March 24, 2025
Like many people, I’m both wary of and intrigued by people who make bombastic claims. Years in the longevity field have taught me caution but also that big claims are
Junevity Is Silencing RNA to Treat Obesity and Diabetes
February 27, 2025
Some longevity biotech companies fit neatly into one of the big buckets we have in this field, like senolytics or cellular reprogramming. Others, such as Junevity, a small spin-out from
Longevity Advocacy in 2025: The Expert Roundup
January 15, 2026
The last installment in our end-of-year series of expert roundups might be the least flashy, but it is arguably no less important than the previous ones dedicated to longevity biotech and geroscience. Public advocacy is a powerful lever. To quote Abraham Lincoln: “Public sentiment is everything.
Geroscience in 2025: The Expert Roundup
January 13, 2026
2025 was a good year for geroscience, marked by rapid strides and critical milestones. Yet, the path wasn’t always smooth: progress in some areas lagged, research hit dead ends, and familiar bottlenecks persisted. Against this backdrop, we asked five prominent geroscientists to share their perspectives on
Longevity Biotech in 2025: The Expert Roundup
January 6, 2026
How did the year 2025 turn out for longevity biotech? Was it surprising or more of the same? Exciting or disappointing? Was the progress fast-moving or excruciatingly slow? What should we expect in 2026? We asked five leading experts to weigh in. Where did longevity biotech
Maximina Yun on the Wonders of the Axolotl
December 19, 2025
Dr. Maximina Yun, principal investigator at Chinese Institutes for Medical Research in Beijing (CIMR), studies some of the most amazing animals in the world: salamanders, a group of amphibians that includes newts and species such as the universally loved axolotl. On top of being cute, salamanders
Andrea Maier on Longevity Medicine for All
October 22, 2025
Dr. Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is a veteran geroscientist and one of the most familiar faces in the rising field of longevity medicine, which aims to translate the early successes of geroscience into clinical practice. Parallel
Sam Sharifi on Fixing Our DNA
October 3, 2025
Among the hallmarks of aging, DNA damage is both one of the most important and one of the hardest to crack. A couple of years ago, when I first learned about Matter Bioworks at a prominent longevity conference, I was amazed at the audacity of the
Joe Betts-Lacroix on Retro Bio and Its Recent AI Advancement
October 2, 2025
Retro Biosciences, one of the hottest startups in the longevity field, was founded about five years ago by the tech entrepreneur Joe Betts-Lacroix with a $180 million investment from his friend Sam Altman, the CEO of OpenAI. Despite its hefty war chest, the company initially pursued
Nir Barzilai: “Positive Evidence for Metformin is Mounting”
August 12, 2025
Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine, among his many other titles, is one of geroscience’s most prominent figures. He is everywhere all at once, seemingly collaborating with the entire world, but is best known
Gabriel Cian on Investment and the 2060 Longevity Forum
July 10, 2025
In this Lifespan interview, we speak with Gabriel Cian, founder of the 2060 Longevity Forum, about how his background in software shaped his views on healthspan innovation, the forum’s approach to scientific and investment credibility, and what he sees as the biggest bottlenecks and opportunities facing
Dr. David Furman on Inflammation and Aging
July 7, 2025
The longevity field hasn’t been very good at naming things, but one notable exception is “inflammaging”: the low-grade chronic inflammation that correlates with aging. Recognition has been growing that inflammation, the ubiquitous reaction of the immune system to various stressors, is a major driver of many
Boyang Wang on Targeting Underfunded Longevity Projects
June 9, 2025
In this interview, Boyang Wang of Immortal Dragons discusses the kinds of projects he wants to fund, ways in which the industry can be encouraged to develop, relationships between the East and West in longevity research and development, and what got him involved in longevity. Hello,
Rejuve.AI: Just Another App or a Longevity Research Network?
June 5, 2025
On its website, Rejuve.AI, a company co-founded by its dynamic CEO, Jasmine Smith, and a renowned AI researcher, Ben Goertzel, promises a lot of things: to “democratize longevity, globally,” to enable you to “take control of your data, and harness its earning potential,” and to “unite
Michael Levin on Bioelectricity in Development and Aging
May 8, 2025
Michael Levin, professor at Tufts University and director of Allen Discovery Center, has been working for years on how bioelectrical patterns affect development and aging. His research proves that this often-overlooked part of biology is immensely important and that mastering its mechanisms might one day do
Joshua “Scotch” McClure: “Infectious Disease Drives Aging”
March 24, 2025
Like many people, I’m both wary of and intrigued by people who make bombastic claims. Years in the longevity field have taught me caution but also that big claims are not necessarily outlandish, and few people make bigger claims than Joshua “Scotch” McClure, founder and CEO
Junevity Is Silencing RNA to Treat Obesity and Diabetes
February 27, 2025
Some longevity biotech companies fit neatly into one of the big buckets we have in this field, like senolytics or cellular reprogramming. Others, such as Junevity, a small spin-out from the University of California, San Francisco, dare to walk an unbeaten path. Junevity pursues the ambitious